Piper Jaffray Companies Begins Coverage on aTyr Pharma, Inc. (LIFE)
Equities research analysts at Piper Jaffray Companies initiated coverage on shares of aTyr Pharma, Inc. (NASDAQ:LIFE) in a note issued to investors on Thursday, Marketbeat.com reports. The firm set an “overweight” rating and a $7.00 price target on the biotechnology company’s stock. Piper Jaffray Companies’ target price would indicate a potential upside of 122.22% from the company’s current price.
LIFE has been the topic of several other reports. Zacks Investment Research upgraded shares of aTyr Pharma from a “hold” rating to a “buy” rating and set a $3.75 target price on the stock in a report on Wednesday, July 12th. ValuEngine cut shares of aTyr Pharma from a “hold” rating to a “sell” rating in a report on Tuesday, August 1st. Finally, BMO Capital Markets set a $4.00 target price on shares of aTyr Pharma and gave the stock a “hold” rating in a report on Tuesday, August 15th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and one has issued a buy rating to the company. The stock has an average rating of “Hold” and an average price target of $4.27.
Shares of aTyr Pharma (LIFE) traded up 3.28% on Thursday, reaching $3.15. 94,347 shares of the company were exchanged. The company’s 50-day moving average is $3.04 and its 200-day moving average is $3.31. aTyr Pharma has a 52 week low of $2.10 and a 52 week high of $4.45. The company’s market capitalization is $75.09 million.
aTyr Pharma (NASDAQ:LIFE) last issued its earnings results on Monday, August 14th. The biotechnology company reported ($0.51) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.57) by $0.06. On average, equities analysts expect that aTyr Pharma will post ($2.18) EPS for the current fiscal year.
In other news, Director Paul Schimmel purchased 94,336 shares of the firm’s stock in a transaction on Thursday, August 31st. The stock was acquired at an average cost of $2.65 per share, with a total value of $249,990.40. Following the completion of the transaction, the director now owns 40,440 shares in the company, valued at approximately $107,166. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CEO John Mendlein purchased 37,736 shares of the firm’s stock in a transaction on Thursday, August 31st. The shares were purchased at an average cost of $2.65 per share, with a total value of $100,000.40. The disclosure for this purchase can be found here. Corporate insiders own 33.30% of the company’s stock.
A hedge fund recently raised its stake in aTyr Pharma stock. Renaissance Technologies LLC raised its position in shares of aTyr Pharma, Inc. (NASDAQ:LIFE) by 1.8% in the 1st quarter, according to the company in its most recent disclosure with the SEC. The fund owned 38,800 shares of the biotechnology company’s stock after buying an additional 700 shares during the quarter. Renaissance Technologies LLC owned about 0.16% of aTyr Pharma worth $136,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 46.66% of the company’s stock.
About aTyr Pharma
aTyr Pharma, Inc is a clinical-stage biotherapeutics company. The Company is engaged in the discovery and clinical development of medicines for patients suffering from severe, rare diseases using its Physiocrine biology, a discovered set of physiological modulators. The Company focuses on the development of Physiocrine-based therapeutics for the treatment of rare diseases, including facioscapulohumeral muscular dystrophy (FSHD) and limb-girdle muscular dystrophy (LGMD) 2B.
Receive News & Ratings for aTyr Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for aTyr Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.